Ardelyx Inc (ARDX) Stock Price, Quote & News

Company Profile

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 745 1700

Website: www.ardelyx.com

Address:

400 Fifth Avenue, Suite 210, Waltham, United States

mkeyankee May. 13 at 1:06 PM

$ARDX https://www.businesswire.com/news/home/20260513899186/en/Assertio-to-Be-Acquired-by-Zydus-Worldwide-DMCC-for-%2423.50-Per-Share-in-Cash

0 · Reply

Lenni_D May. 13 at 12:46 PM

$ARDX ASRT already had 60m cash and added 35m in this process by selling assets. Debt approximately 40 m if memory serves. So this is an even smaller deal for Zydus So this doesn’t affect the ability to buy ARDX but of course kind of kills the momentum for the rumor from creating the subsidiary. Assertio relies on digital marketing and has a very small sales force. So this is a completely different kind of merger if Zydus is looking for a real sales organization to sell their products in the US. But it looks like a good deal for Zydus.

0 · Reply

Arcides May. 13 at 12:36 PM

$ARDX pathetic...

0 · Reply

pv90377 May. 13 at 12:27 PM

$ARDX disappointing.

0 · Reply

Cameohitch May. 13 at 12:22 PM

$ARDX "Notably, Dr. Block has been among the first nephrologists to enroll patients in several landmark clinical trials and therapeutic innovations, including enrolling the earliest patients in Phase 2 and Phase 3 clinical trials for Cinacalcet, Parsabiv®, Tenapanor, and VAFSEO, while also designing and conducting randomized trials of other practice- changing therapeutics like HIF-PHIs, Sevelamer, and Ferric citrate. The impact of his work is immeasurable." https://www.prnewswire.com/news-releases/us-renal-care-associate-chief-medical-officer-geoffrey-a-block-md-fasn-awarded-2026-aakp-medal-of-excellence-for-lifetime-contributions-to-kidney-care-302770089.html

0 · Reply

M_OF_E May. 13 at 12:05 PM

$ARDX Zydus is buying Assertio (ASRT) for a total of about $170M

4 · Reply

bernardbaruch May. 13 at 11:45 AM

$ARDX yawn fart belch. Watching MMs has become my spectator sport.

1 · Reply

Gusnbrew May. 13 at 4:54 AM

$ARDX c’mon baby. Another retest of 8$. Cup formed at 10$. Lil’ handle and a rocket would be nice in the next 12 months. Holding strong

0 · Reply

Paul_Volcker May. 13 at 2:17 AM

$ARDX Don't know if this is new news or not but wanted to post regardless - 05/12/2026 09:55 AM Filing State Street (ARDX) reports 13.6M-share | 5.5% stake via advisory entities Rhea-AI Summary State Street Corporation reported beneficial ownership of 13,604,307 shares of Ardelyx, Inc. common stock, representing 5.5% of the class. The filing shows shared voting power of 12,897,628 shares and shared dispositive power of 13,604,307 shares, with ownership reported on behalf of multiple State Street advisory subsidiaries.

3 · Reply

donkeykongreturns May. 13 at 12:48 AM

$ARDX https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change They should do a study on this with Tena - gut dysbiosis and insulin insensitivity connection may have a connection

0 · Reply

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

2026-04-30T21:07:15.000Z - 12 days ago

Ardelyx reports Q1 EPS (15c), consensus (14c)

Apr 30, 2026, 4:30 PM EDT - 12 days ago

Ardelyx Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:01 PM EDT - 12 days ago

Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 27, 2026, 8:01 AM EDT - 16 days ago

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings

Apr 23, 2026, 8:01 AM EDT - 20 days ago

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

2026-04-22T11:54:28.000Z - 21 days ago

Jade Biosciences appoints Edward Conner as chief medical officer

JBIO

2026-04-20T12:50:41.000Z - 23 days ago

Ardelyx appoints Ettenberg as Chief Legal Officer

Apr 20, 2026, 8:00 AM EDT - 23 days ago

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

BMY

Apr 16, 2026, 8:01 AM EDT - 27 days ago

Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

2026-04-01T12:17:42.000Z - 6 weeks ago

Ardelyx appoints Rajani Dinavahi as chief medical officer

Apr 1, 2026, 8:01 AM EDT - 6 weeks ago

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Mar 10, 2026, 4:20 PM EDT - 2 months ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:05 PM EDT - 2 months ago

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

2026-03-05T13:09:46.000Z - 2 months ago

Zevra Therapeutics appoints Renz as Chief Financial Officer

ZVRA

Mar 4, 2026, 8:00 AM EST - 2 months ago

Ardelyx to Participate in Upcoming Investor Conferences

2026-02-24T13:18:35.000Z - 2 months ago

Ardelyx, LPGA announce multi-year partnership

Feb 24, 2026, 8:00 AM EST - 2 months ago

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

2026-02-20T11:12:08.000Z - 2 months ago

Ardelyx price target raised to $18 from $10 at H.C. Wainwright

2026-02-19T22:00:37.000Z - 2 months ago

Ardelyx reports Q4 EPS 0c, consensus 1c

Feb 19, 2026, 4:30 PM EST - 2 months ago

Ardelyx Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:01 PM EST - 2 months ago

Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

2026-02-19T20:45:39.000Z - 2 months ago

Ardelyx options imply 14.7% move in share price post-earnings

Feb 5, 2026, 8:00 AM EST - 3 months ago

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

2026-02-03T13:41:00.000Z - 3 months ago

Ardelyx receives new patent for Tenapanor

Feb 3, 2026, 8:29 AM EST - 3 months ago

Ardelyx Receives New Patent for Tenapanor

2026-01-29T14:35:34.000Z - 3 months ago

Ardelyx price target raised to $13 from $10 at TD Cowen

2026-01-28T13:38:18.000Z - 3 months ago

Ardelyx announces first patient dosed in ACCEL

Jan 28, 2026, 8:29 AM EST - 3 months ago

First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

2026-01-27T11:25:47.000Z - 3 months ago

Ardelyx price target raised to $15 from $8 at Jefferies

2026-01-09T12:45:43.000Z - 4 months ago

Ardelyx price target raised to $14 from $11 at Citi

2026-01-09T11:00:13.000Z - 4 months ago

Ardelyx price target raised to $17 from $14 at BTIG

2026-01-08T21:35:56.000Z - 4 months ago

Ardelyx upgraded to Overweight from Neutral at Piper Sandler

2026-01-08T21:35:25.000Z - 4 months ago

Ardelyx upgraded to Overweight from Neutral at Piper Sandler

2026-01-08T17:50:15.000Z - 4 months ago

Ardelyx price target raised to $19 from $16 at Raymond James

Jan 8, 2026, 8:30 AM EST - 4 months ago

Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook

Nov 19, 2025, 11:30 AM EST - 6 months ago

Ardelyx Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 11:30 AM EST - 6 months ago

Ardelyx Transcript: Wedbush Rewind ASN 2025 Conference

Nov 7, 2025, 4:05 PM EST - 6 months ago

Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

Nov 5, 2025, 8:00 AM EST - 6 months ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Nov 4, 2025, 8:00 AM EST - 6 months ago

Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

Oct 30, 2025, 4:30 PM EDT - 6 months ago

Ardelyx Earnings Call Transcript: Q3 2025

Oct 30, 2025, 4:01 PM EDT - 6 months ago

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 28, 2025, 8:01 AM EDT - 7 months ago

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting

Oct 21, 2025, 8:00 AM EDT - 7 months ago

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology's Kidney Week

Oct 13, 2025, 8:35 AM EDT - 7 months ago

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

Oct 13, 2025, 8:30 AM EDT - 7 months ago

Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

Sep 9, 2025, 11:30 AM EDT - 8 months ago

Ardelyx Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:00 AM EDT - 8 months ago

Ardelyx Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 8:35 AM EDT - 8 months ago

Ardelyx Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 1:00 PM EDT - 8 months ago

Ardelyx Transcript: Citi's Biopharma Back to School Conference

Aug 4, 2025, 4:30 PM EDT - 10 months ago

Ardelyx Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:08 PM EDT - 10 months ago

Ardelyx Announces Changes to the Executive Leadership Team

Aug 4, 2025, 4:01 PM EDT - 10 months ago

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 21, 2025, 8:00 AM EDT - 10 months ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Jun 4, 2025, 8:10 AM EDT - 1 year ago

Ardelyx Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 4:05 PM EDT - 1 year ago

Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer

May 21, 2025, 8:00 AM EDT - 1 year ago

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

May 6, 2025, 8:01 AM EDT - 1 year ago

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

May 1, 2025, 4:30 PM EDT - 1 year ago

Ardelyx Earnings Call Transcript: Q1 2025

May 1, 2025, 4:01 PM EDT - 1 year ago

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 24, 2025, 8:01 AM EDT - 1 year ago

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

Apr 10, 2025, 4:02 PM EDT - 1 year ago

Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

Mar 31, 2025, 4:03 PM EDT - 1 year ago

Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings

Mar 13, 2025, 10:00 AM EDT - 1 year ago

Ardelyx Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 13, 2025, 8:02 AM EDT - 1 year ago

Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Ardelyx Transcript: Leerink Global Healthcare Conference 2025

Mar 3, 2025, 9:50 AM EST - 1 year ago

Ardelyx Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Tenapanor Approved in China for Hyperphosphatemia

Feb 20, 2025, 8:00 AM EST - 1 year ago

Ardelyx Earnings Call Transcript: Q4 2024

Feb 20, 2025, 7:30 AM EST - 1 year ago

Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 8:01 AM EST - 1 year ago

Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

mkeyankee May. 13 at 1:06 PM

$ARDX https://www.businesswire.com/news/home/20260513899186/en/Assertio-to-Be-Acquired-by-Zydus-Worldwide-DMCC-for-%2423.50-Per-Share-in-Cash

0 · Reply

Lenni_D May. 13 at 12:46 PM

0 · Reply

Arcides May. 13 at 12:36 PM

$ARDX pathetic...

0 · Reply

pv90377 May. 13 at 12:27 PM

$ARDX disappointing.

0 · Reply

Cameohitch May. 13 at 12:22 PM

0 · Reply

M_OF_E May. 13 at 12:05 PM

$ARDX Zydus is buying Assertio (ASRT) for a total of about $170M

4 · Reply

bernardbaruch May. 13 at 11:45 AM

$ARDX yawn fart belch. Watching MMs has become my spectator sport.

1 · Reply

Gusnbrew May. 13 at 4:54 AM

$ARDX c’mon baby. Another retest of 8$. Cup formed at 10$. Lil’ handle and a rocket would be nice in the next 12 months. Holding strong

0 · Reply

Paul_Volcker May. 13 at 2:17 AM

3 · Reply

donkeykongreturns May. 13 at 12:48 AM

$ARDX https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change They should do a study on this with Tena - gut dysbiosis and insulin insensitivity connection may have a connection

0 · Reply

Kdeinv123 May. 13 at 12:00 AM

$ARDX I am a long term holder of ARDX and have a large position with a cost basis under $3. Have held several years and expect it to hit double digits at some point in the near future. I also have a more speculative position in SLS which has a promising cancer drug the appears to extend the life of myeloid leukemia patients. It is up 20% after hours and there is a large short position. They reported 78 events and need 2 more to reach 80 under their REGAL study. The REGAL study is a pivotal Phase 3 trial evaluating galinpepimut‑S (GPS), a WT1‑targeted immunotherapy, in patients with acute myeloid leukemia (AML) who have achieved second complete remission (CR2) or second complete remission with incomplete platelet recovery (CRp2) after salvage therapy. Have a much smaller position but willing to hold based on their prospects going forward. Any ARDX holders follow this one and have any input as to their prospects going forward? Thanks in Advance..

1 · Reply

5StarTrader May. 12 at 11:59 PM

$ARDX Market Makers are typically business subsidiaries of large Investment Banks & Brokerage Firms. They are the ones that do IPO’s & secondary offerings and let a few choice clients in on the free money. In turn, the clients, which are mostly investment funds who want more free money, give the IB’s & IF’s large orders to fill at limit prices for a fat fee. To fill orders, the MM Mafia need sellers, who typically don’t know how the game is played. During the last quarter, the MM Mafia filled orders for a 25 million share increase in total client holdings…by getting retail sellers to get out of the way of a sure thing. Welcome to Wall Street…

1 · Reply

wildcard55 May. 12 at 8:34 PM

$ARDX Seems to me that the longer things go without a court decision, the better it probably has to be for us. It's hard for me to think differently here. If this was such an easy case to decide, I think we would've seen a decision released by now.

3 · Reply

OldManLogan May. 12 at 8:29 PM

$ARDX Interesting. I asked my AI buddy, Chad, to share his thoughts on your post. The only thing he took issue with was the 'victory is inevitable' closing remark, he thought everything else seemed reasonable. If they pulled this off, I'd be a buyer of any shares available under $12... at the same time, if there is any meaningful pull back on a rejected appeal, I'll double my position... if there is investment karma, ARDX should win... Raab is like the stock market equivalent of John Wick.

1 · Reply

ToadTrader May. 12 at 8:10 PM

$ARDX Interesting Day! Got tied up elsewhere, while otherwise waiting for a bounce to run upwards! Will be waiting for the price action shifts from consolidation to "get on up the hill!" Stay Safe... understand your risk and work your plan! CHEERS!

1 · Reply

qwertynuts May. 12 at 6:40 PM

$ARDX floor is here, now. Excited for the future and beyond, 1500 shares accumulated.

1 · Reply

findingthestock May. 12 at 6:25 PM

$ARDX Makary is out as FDA commissioner Makary’s tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers, physicians and patient groups on regulatory decisions.

0 · Reply

Burning_Cash May. 12 at 6:05 PM

$ARDX Hate myself for actually being glad this is green. Barely. But 6s, man! 6s!

2 · Reply

Berolina May. 12 at 5:35 PM

$ARDX has anyone ever accientally dne this and either been unjustifiably happy/ or sad. Asking for a friend.

2 · Reply

bernardbaruch May. 12 at 3:46 PM

$ARDX muscle up Nia

1 · Reply

MedHS55 May. 12 at 3:14 PM

$ARDX Somehow I doubt that State Street, which I'm sure talks with management more than any of us, spends hours on this board, before deciding to add 2 million shares. 😉

2 · Reply

IN0V8 May. 12 at 2:43 PM

$ARDX Added at $6.52

0 · Reply

Market Cap	1.63B
Revenue (ttm)	407.32M
Net Income (ttm)	-61.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15.12%
Debt to Equity Ratio	1.37

Volume	1,822,700
Avg Vol	3,663,692
Day's Range	N/A - N/A
Shares Out	247.03M
Stochastic %K	43%
Beta	0.62
Analysts	Strong Sell
Price Target	$16.44